GTx Phase IIIb Study Will Evaluate Therapy For Prostate Cancer Treatment Side Effects
This article was originally published in The Pink Sheet Daily
Executive Summary
GTx is initiating an extension of its Phase III clinical trial of Acapodene in prostate cancer patients.
You may also be interested in...
GTx To File NDA For Acapodene In Early 2008
Phase III interim analysis finds the selective estrogen receptor modulator lowers cholesterol associated with androgen deprivation therapy for prostate cancer.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.